KLRC1 and neoplasm: The HLA-B–HLA-E–NKG2A pathway has a role in the NK cell surveillance of tumor cells [57] and is a target for cancer immunotherapy by inhibitory checkpoint blockade with monoclonal anti-NKG2A antibodies that enhance both NK cell and T cell activity against tumor cells [58].